Literature DB >> 17116093

Chronic frequent headache in the general population: prevalence and associated factors.

N J Wiendels1, A Knuistingh Neven, F R Rosendaal, P Spinhoven, F G Zitman, W J J Assendelft, M D Ferrari.   

Abstract

We studied the prevalence and short-term natural course of chronic frequent headache (CFH) in the general population and identified risk factors. In the Netherlands everyone is registered at a single general practice. We sent questionnaires to all persons (n = 21 440) aged 25-55 years, registered at 16 general practices. We compared the characteristics of 177 participants with CFH (>14 headache days/month for >3 months) with 141 participants with infrequent headache (1-4 days/month) and 526 without headache (<1 day/month). The prevalence of CFH was 3.7% [95% confidence interval (CI) 3.4, 4.0]. In 5 months, 12% showed a clinically relevant decrease to <7 days/month. In both headache groups 70% were women vs. 41% in the group without headache. Compared with the group with infrequent headache, the CFH group had more subjects with low educational level [35% vs. 11%; odds ratio (OR) 4.3, 95% CI 2.3, 7.8], medication overuse (62% vs. 3%; OR 38.4, 95% CI 13.8, 106.9), sleeping problems (44% vs. 8%; OR 8.1, 95% CI 3.6, 18.1), a history of head/neck trauma (36% vs. 14%; OR 4.0, 95% CI 2.2, 7.1), high scores on the General Health Questionnaire (62% vs. 34%; OR 2.7, 95% CI 1.3, 3.6) and more smokers (45% vs. 19%; OR 3.1, 95% CI 1.9, 5.3). We conclude that headache frequency fluctuates. CFH is common and associated with overuse of analgesics, psychopathology, smoking, sleeping problems, a history of head/neck trauma and low educational level. Female sex is a risk factor for headache, not for chronification of headache.

Entities:  

Mesh:

Year:  2006        PMID: 17116093     DOI: 10.1111/j.1468-2982.2006.01210.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  36 in total

1.  Cigarette smoking and self-assessed upper airway health.

Authors:  Thomas Kjærgaard; Milada Cvancarova; Sverre K Steinsvåg
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-05-29       Impact factor: 2.503

2.  Sinus venous stenosis-associated idiopathic intracranial hypertension without papilledema as a powerful risk factor for progression and refractoriness of headache.

Authors:  Roberto De Simone; Angelo Ranieri; Silvana Montella; Mario Marchese; Vincenzo Bonavita
Journal:  Curr Pain Headache Rep       Date:  2012-06

Review 3.  A Critical Evaluation on MOH Current Treatments.

Authors:  Andrea Negro; Martina Curto; Luana Lionetto; Simona Guerzoni; Luigi Alberto Pini; Paolo Martelletti
Journal:  Curr Treat Options Neurol       Date:  2017-08-15       Impact factor: 3.598

Review 4.  Medication-overuse headache: a perspective review.

Authors:  Maria Lurenda Westergaard; Signe Bruun Munksgaard; Lars Bendtsen; Rigmor Højland Jensen
Journal:  Ther Adv Drug Saf       Date:  2016-06-30

Review 5.  Medication-overuse headache: epidemiology, diagnosis and treatment.

Authors:  Espen Saxhaug Kristoffersen; Christofer Lundqvist
Journal:  Ther Adv Drug Saf       Date:  2014-04

Review 6.  Medication Overuse Headache: The Reason of Headache That Common and Preventable.

Authors:  Elif Kocasoy Orhan; Betül Baykan
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

Review 7.  Prevalence of headache in Europe: a review for the Eurolight project.

Authors:  Lars Jacob Stovner; Colette Andree
Journal:  J Headache Pain       Date:  2010-05-16       Impact factor: 7.277

8.  Combination of acupuncture and spinal manipulative therapy: management of a 32-year-old patient with chronic tension-type headache and migraine.

Authors:  Bahia A Ohlsen
Journal:  J Chiropr Med       Date:  2012-09

Review 9.  Caffeine and headaches.

Authors:  Robert E Shapiro
Journal:  Curr Pain Headache Rep       Date:  2008-08

Review 10.  Medication overuse headache.

Authors:  Zaza Katsarava; Dagny Holle; Hans-Christoph Diener
Journal:  Curr Neurol Neurosci Rep       Date:  2009-03       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.